Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme

Prostate Cancer and Prostatic Diseases volume 15, pages 202–209 (2012)Cite this article

Abstract

Background:

We previously reported the diagnostic efficacy of the age- and prostate volume-adjusted prostate biopsy method (the adjusted biopsy method). Here, we developed a new nomogram for predicting cancer probability at initial biopsy using the adjusted method.

Methods:

Between 2002 and 2010, 1059 Japanese men with PSA levels between 1.1 and 40 ng ml−1 and biopsied for the first time using the adjusted method at Gunma University Hospital were enrolled. All subjects underwent digital rectal examination (DRE) and transrectal ultrasonography (TRUS). Data from the initial 849 subjects were used for development of the nomogram and those from the final 210 subjects were used for internal validation. External validation was conducted using data from two affiliated hospitals where the same adjusted biopsy method was used. The nomogram was developed through logistic regression analysis, and predictive accuracy and performance characteristics were assessed using the area under the curve (AUC) of the receiver operating characteristics and calibration plots. Furthermore, we compared the predictive accuracy of the newly developed nomogram with the ‘Prostate Risk Indicator’ using the development data set, as well as the two external data sets.

Results:

The AUC of the logistic regression-based nomogram was significantly higher than those of any single clinical parameter. External validation showed significant correlations with the present model. The AUC-receiver operating characteristic of the ‘Prostate Risk Indicator’ was the second largest following the new nomogram using the development data set and one external data set and almost equal to the new nomogram using the other external data set.

Conclusions:

Nevertheless the present model does not include somewhat subjective findings on TRUS abnormality, which is necessary for the estimation by ‘Prostate Risk Indicator’, the predictive accuracy of the present simple nomogram could be excellent enough to contribute to accurate shared decision-making between doctors and men who are candidates for the adjusted biopsy scheme.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–1328.

    Article  Google Scholar 

  2. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725–732.

    Article  Google Scholar 

  3. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE . A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998; 159: 920–924.

    Article  CAS  Google Scholar 

  4. Ito K, Ohi M, Yamamoto T, Miyamoto S, Kurokawa K, Fukabori Y et al. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1–10.0 ng/ml. Cancer 2002; 95: 2112–2119.

    Article  CAS  Google Scholar 

  5. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW . Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/ml. Urology 1999; 54: 709–713.

    Article  CAS  Google Scholar 

  6. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2011; 173: 1930–1934.

    Article  Google Scholar 

  7. Suzuki H, Komiya A, Kamiya N, Imamoto T, Kawamura K, Miura J et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006; 67: 131–136.

    Article  Google Scholar 

  8. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007; 25: 3582–3588.

    Article  CAS  Google Scholar 

  9. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V et al. Development and validation of an extended 10-core biopsy nomogram. Eur Urol 2007; 52: 436–445.

    Article  Google Scholar 

  10. Kawakami S, Koga F, Fujii Y, Saito K, Yamamoto S, Tatokoro M et al. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int J Urol 2008; 15: 1055–1060.

    Article  Google Scholar 

  11. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 2008; 54: 610–611.

    Article  Google Scholar 

  12. Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/ml. Int J Urol 2008; 15: 598–603.

    Article  CAS  Google Scholar 

  13. Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res 2007; 28: 2487–2492.

    Google Scholar 

  14. Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D et al. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010; 57: 1–8.

    Article  Google Scholar 

  15. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79–85.

    Article  Google Scholar 

  16. Schmid HP, McNeal JE, Stamey TA . Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031–2040.

    Article  CAS  Google Scholar 

  17. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE . The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288–294.

    Article  CAS  Google Scholar 

  18. Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000; 56: 278–282.

    Article  CAS  Google Scholar 

  19. Eskew LA, Bare RL, McCullough DL . Systematic 5 region biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199–202.

    Article  CAS  Google Scholar 

  20. Presti JC, Chang JJ, Bhargava V, Shinohara K . The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163–167.

    Article  Google Scholar 

  21. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 1554–1559.

    Article  CAS  Google Scholar 

  22. Guichard G, Larre S, Gallina A, Lazar A, Faucon H, Chemama S et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007; 52: 430–435.

    Article  Google Scholar 

  23. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010; 58: 851–864.

    Article  Google Scholar 

  24. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan Jr ED . The influence of prostate size on cancer detection. Urology 1995; 46: 831–836.

    Article  CAS  Google Scholar 

  25. de la Taille A, Antiphon P, Salomon L, Cherfan M, Porcher R, Hoznek A et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003; 61: 1181–1186.

    Article  Google Scholar 

  26. Scattoni V, Roscigno M, Raber M, Dehò F, Maga T, Zanoni M et al. Initial extended transrectal prostate biopsy—are more prostate cancers detected with 18 cores than 12 cores? J Urol 2008; 179: 1327–1331.

    Article  Google Scholar 

  27. Remzi M, Fong YK, Dobrovits M, Anagnostou T, Seitz C, Waldert M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volumes. J Urol 2005; 174: 1256–1261.

    Article  Google Scholar 

  28. Jiang J, Colli J, El-Galley R . A simple method for estimating the optimal number of prostate biopsy cores needed to maintain high cancer detection rates while minimizing unnecessary biopsy sampling. J Endourol 2010; 24: 143–147.

    Article  Google Scholar 

  29. Bassler TJ, Orozco R, Bassler GJ, O’Dowd GJ, Stamey TA . Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology 1998; 52: 1064–1069.

    Article  Google Scholar 

  30. Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M . Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/ml: development of a novel pre-biopsy nomogram. Int J Urol 2010; 17: 274–280.

    Article  CAS  Google Scholar 

  31. Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K . Prostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy. Int J Urol 2009; 16: 561–565.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author information

Authors and Affiliations

  1. Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan

    M Nomura, K Ito, M Miyakubo, Y Sekine & K Suzuki

  2. Department of Urology, Tone Chuo Hospital, Numata, Japan

    Y Tamura

  3. Department of Urology, Gunma Cancer Center, Ohta, Japan

    N Shimizu

  4. Faculty of Social and Information Studies, Gunma University, Maebashi, Gunma, Japan

    S Aoki

Authors
  1. M Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Miyakubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Ito.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nomura, M., Ito, K., Miyakubo, M. et al. Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme. Prostate Cancer Prostatic Dis 15, 202–209 (2012). https://doi.org/10.1038/pcan.2011.62

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.62

Keywords

This article is cited by

Search

Advanced search

Quick links